<?xml version="1.0" encoding="UTF-8"?>
<p>The IMPAACT network serves as an excellent example of how a group focused on therapeutics in pregnant women can make major strides to close the evidence gap (
 <bold>
  <xref rid="pmed.1002882.t002" ref-type="table">Table 2</xref>
 </bold>). Establishing a global TB registry and inclusion of pregnant women into relevant Phase III TB trials should be the next step. TB therapeutic protocols under development should be reviewed by experts in the care of TB in pregnant women, maternalâ€“fetal medicine specialists, regulatory authorities, and bioethicists who can further comment on the risks and benefits of including pregnant women during the trial planning stage.
</p>
